Amer Zeidan: Looking Forward to Sharing New AML Data at ESH 2026
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn:
“I look forward to presenting in a podium talk the updated results from our KOMET 007 phase 1/2 study combining the novel oral menin inhibitor ziftomenib with intensive chemotherapy 7+3 in fit patients with newly diagnosed acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements at the European Society of Hematology meeting ESH2026 in Stockholm.
The early results from this study have led to the ongoing registrational-intent and global randomized phase 3 study KOMET 017 of the same combination which I am honored to be the steering committee chair and where at Yale University we were the first center to open and to enroll the first patient globally.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026